Centro Paulista de Investigação Clínica - CEPIC

Centro Paulista de Investigação Clínica - CEPIC
R. Moreira e Costa, 342 - Ipiranga, São Paulo - SP, 04266-010
Select an option

Our team

Medical staff
Gabrielle Martins Arantes da Silva
Maria Eduarda Afonso Penna
Bruno Paiva
Amanda Silva
Cristiano Augusto de Freitas Zerbini
Bruno Ruivo
Marcos Soares
Breno Balabem Alves
Natalia Ribeiro
Andrea Barranjard Vannucci Lomonte
Agatha Sálvio Fernandes
Tiago Freitas
Vanessa Padua
Mariana Ribeiro
Nathaly Silva
Flora Maria D’Andréa Marcolino
Henrique Alves Cusin
Vitorya Jennifer Melo
Nathalia Fossaluza Gonçalves
Nathalia Martins Beiro
Giovanna Tamarindo da Silveira
Erlon Silva
Fernando Brunori
Sofia Helena Martins Velazquez
Carolyne Marcela Pires
Fernanda Audine Moor Pinheiro
Sabrina Taniguchi
Eduarda da Silva
Danielle Karini de Souza Costa
Giovanna Moreira Sampaio
Giulia Herrera
Gabriela Larissa Oliveira

Open studies

Cardiovascular disease
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity - MARITIME-CV - AmgenSee more
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a) - MOVE-Lp(a) - Eli Lilly and CompanySee more
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes) - ATTAIN-Outcomes - Eli Lilly and CompanySee more
Obesity
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity - MARITIME-CV - AmgenSee more
Elevated Lipoprotein A
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a) - MOVE-Lp(a) - Eli Lilly and CompanySee more
Renal disease
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes) - ATTAIN-Outcomes - Eli Lilly and CompanySee more
LinkedinInstagramFacebook
Terms and ConditionsPrivacy Policy